GlassScriptPhysician profile
Jeffrey D Gellis
NPI 1144488958
$4,645.94
in general payments reported to CMS, 2019-2025
29 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $39.37 · 2021: $177 · 2022: $350 · 2023: $897 · 2024: $1,093 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.76 |
| Education | $129.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.50 | 2022-2025 | |
| Janssen Biotech, INC. | $409.75 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $307.72 | 2023-2025 | |
| Pfizer INC. | $259.46 | 2019-2025 | |
| Madrigal Pharmaceuticals | $243.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $223.81 | 2019-2025 | Watchman Access System |
| Qol Medical, LLC | $214.52 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.50 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $149.97 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $145.82 | 2022-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $116.91 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $99.56 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $97.30 | 2024-2025 | Omvoh |
| Sandoz INC. | $95.17 | 2023-2025 | Hyrimoz |
| Daiichi Sankyo INC. | $91.04 | 2021-2024 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $82.62 | 2023-2025 | Yuflyma, Vegzelma |
| Aimmune Therapeutics, INC. | $75.27 | 2023-2025 | Zenpep |
| Organon LLC | $73.49 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $65.79 | 2019-2024 | |
| Vivus LLC | $54.50 | 2025 | Qsymia |
| Braintree Laboratories, INC. | $49.34 | 2022-2024 | Sutab, Suflave |
| Amgen INC. | $32.06 | 2022-2025 | Uplizna |
| Evoke Pharma, INC. | $25.30 | 2022-2024 | |
| Novo Nordisk INC | $20.13 | 2025 | Wegovy |
| Celgene Corporation | $18.78 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $17.59 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.37 | 2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $13.04 | 2022 | |
| Fresenius Kabi USA, LLC | $12.91 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.